Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04344444 · ClinicalTrials.gov registry record · Phase 3
Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease
A Phase 3 study, sponsored by LCMC Health.
- Terminated
- Registry status
- Phase 3
- Development phase
- 22
- Enrollment target
NCT04344444 is a Phase 3 study that was terminated before completion, run by LCMC Health. The registered enrollment target is 22 participants.
The verdict
NCT04344444, a Phase 3 study, was terminated before completion, sponsored by LCMC Health.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 22 participants
- Enrollment target
Study Summary
This study proposes to evaluate clinical outcomes and viral load in COVID-19 infected patients with early moderate and severe disease admitted to the hospital and randomized to one of three arms. Patients will be randomized to supportive care, OR hydroxychloroquine alone, OR hydroxychloroquine and azithromycin.
Interventions
- DRUG Azithromycin
- DRUG Hydroxychloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2020-04-13 |
| Est. Completion | 2022-01-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04344444
The ClinicalTrials.gov registry entry for NCT04344444 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LCMC Health, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Azithromycin is the first listed.
NCT04344444 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04344444 about?
NCT04344444 is a clinical study titled "Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease". This study proposes to evaluate clinical outcomes and viral load in COVID-19 infected patients with early moderate and severe disease admitted to the hospital and randomized to one of three arms. Patients will be randomized to supportive care, OR hydroxychloroquine alone, OR hydroxychloroquine and a...
What is the current status of trial NCT04344444?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 22 participants. The study started on 2020-04-13. Estimated completion is 2022-01-05.
What interventions are being tested in trial NCT04344444?
The interventions under investigation include: Azithromycin (DRUG), Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT04344444?
This trial is sponsored by LCMC Health, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.